Edition:
United Kingdom

Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Global Select Market

1.72USD
19 Apr 2018
Change (% chg)

$-0.01 (-0.87%)
Prev Close
$1.73
Open
$1.73
Day's High
$1.75
Day's Low
$1.71
Volume
14,481
Avg. Vol
218,813
52-wk High
$9.55
52-wk Low
$1.51

Select another date:

Mon, Mar 12 2018

BRIEF-Advaxis Reports Q1 Loss Per Share $0.49

* ADVAXIS REPORTS FISCAL 2018 FIRST QUARTER FINANCIAL RESULTS AND ANNOUNCES CLINICAL HOLD IN AXALIMOGENE FILOLISBAC PHASE 1/2 COMBINATION STUDY WITH ASTRAZENECA’S IMFINZI® (DURVALUMAB)

BRIEF-Advaxis Prices $20.0 Mln Public Offering Of Common Stock

* ADVAXIS PRICES $20.0 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Advaxis Announces Proposed Public Offering Of Common Stock

* ADVAXIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Advaxis Expects To Report $59.4 Million Of Cash, Cash Equivalents And Investments As Of Jan 31

* ADVAXIS INC SAYS EXPECTS TO REPORT THAT IT HAD $59.4 MILLION OF CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JANUARY 31, 2018 - SEC FILING Source text: (http://bit.ly/2BHztlx) Further company coverage:

BRIEF-Advaxis Submits Conditional MAA For Second-Line Metastatic Cervical Cancer Treatment In European Union

* ADVAXIS SUBMITS CONDITIONAL MARKETING AUTHORIZATION APPLICATION FOR AXALIMOGENE FILOLISBAC FOR THE SECOND-LINE TREATMENT OF METASTATIC CERVICAL CANCER IN EUROPEAN UNION

BRIEF-Advaxis Says Expects Its Current Cash Position Will Be Sufficient To Fund Its Business Plan Into Fiscal 2019

* ADVAXIS REPORTS FISCAL YEAR 2017 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

Select another date: